No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ZNTL240517C17500
- 0.65
- 0.000.00%
15min DelayTrading Mar 15 15:04 ET
0.00High0.00Low
0.00Open0.65Pre Close0 Volume6 Open Interest17.50Strike Price0.00Turnover260.58%IV46.14%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.65Time Value100Contract SizeAmericanOptions Type0.2608Delta0.0654Gamma19.11Leverage Ratio-0.0970Theta0.0006Rho4.98Eff Leverage0.0062Vega
Intraday
- 5D
- 1D
News
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Zentalis Pharmaceuticals (ZNTL) and Paragon 28 (FNA)
Buy Rating on Zentalis Pharmaceuticals Amid High Expectations for Azeno Drug Trials
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
Zentalis Pharmaceuticals Price Target Cut to $40.00/Share From $46.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Zentalis Pharma, Lowers Price Target to $40
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma with a Buy and lowers the price target from $46 to $40.
Comments
The satisfactory 2.7 years cash runway is overshadowed by increased cash burn rate of 19%. The firm's potential to raise funds for growth via new shares may entail dilution of existing ones. Close monitoring of Zentalis Pharmaceuticals' cash burn situation advised.
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Gainers:
• $Enphase Energy(ENPH.US$ +8.2% (earnings reports)
• $Zentalis Pharmaceuticals(ZNTL.US$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $Ternium(TX.US$ +6.1% (earnings reports)
• $PureCycle Technologies(PCT.US$ +5% (SEC concludes investigation without further action)
• $Alliance Resource(ARLP.US$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US$ +4.5% (cu...
• $Enphase Energy(ENPH.US$ +8.2% (earnings reports)
• $Zentalis Pharmaceuticals(ZNTL.US$ +7.6% (announces $25 mln equity investment from Pfizer (PFE); enters into development collaboration for ZN-c3)
• $Ternium(TX.US$ +6.1% (earnings reports)
• $PureCycle Technologies(PCT.US$ +5% (SEC concludes investigation without further action)
• $Alliance Resource(ARLP.US$ +4.7% (increases dividend; provides prelim qtrly results)
• $Digital World Acquisition Corp(DWAC.US$ +4.5% (cu...
14
1
Upgrades
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
• $Banc of California(BANC.US$: Raymond James Upgrades to Outperform from Market Perform - PT $22
• $Cullen/Frost Bankers(CFR.US$: Raymond James Upgrades to Outperform from Market Perform
• $W.W. Grainger(GWW.US$: Wolfe Research Upgrades to Outperform from Peerperform
• $Invitation Homes Inc(INVH.US$: Evercore ISI Upgrades to Outperform from In Line - PT $46 (from $44)
• $PCB Bancorp(PCB.US$: Raymond James Upgrades to Outperform from Market Perfor...
7
Read more